Nimesulida Oara (Nimesulide)

Nimesulide selectively blocks the cyclo‑oxygenase‑2 (COX‑2) enzyme, which limits the production of prostaglandins—chemical mediators that cause pain, fever, and inflammation. By reducing prostaglandin levels, the drug diminishes the sensory signals of pain and the physiological processes that lead to swelling and fever.

The exact dosage of Nimesulida Oara is determined by the prescribing clinician based on the patient’s age, weight, medical condition, and response to therapy. Healthcare professionals follow local prescribing guidelines and adjust the regimen as needed for safety and effectiveness.

The safety of nimesulide in pregnancy and lactation has not been established. It is generally advised to avoid using Nimesulida Oara during pregnancy, especially in the third trimester, and while breastfeeding unless the potential benefit outweighs the possible risk as judged by a qualified healthcare provider.

To request Nimesulida Oara, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nimesulide is a COX‑2‑selective NSAID, offering analgesic and anti‑inflammatory effects similar to ibuprofen or diclofenac but with a slightly different safety profile. Its relative COX‑2 selectivity may reduce gastrointestinal irritation compared with non‑selective NSAIDs, yet it still carries risks of liver toxicity and should be used under medical supervision.

Nimesulida Oara should be stored at room temperature, below 25 °C (77 °F). Keep the tablets in the original container, protect them from moisture, heat and direct sunlight, and ensure they are out of reach of children.

Nimesulida Oara is taken orally, usually with a full glass of water. It can be taken with or without food, but patients who experience stomach upset may benefit from taking it with meals. The exact timing and frequency are set by the prescribing clinician.

The most serious adverse events linked to Nimesulida Oara include hepatotoxicity (liver injury), severe gastrointestinal bleeding or ulceration, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored for signs of liver dysfunction, abdominal pain, or unusual skin changes.

Nimesulida Oara is contraindicated in patients with known hypersensitivity to nimesulide or other NSAIDs, active peptic ulcer disease, severe liver or kidney impairment, and in children younger than 12 years. It should also be avoided in pregnant women, especially during the third trimester, unless a physician determines that the benefit outweighs the risk.